Single-agent retifanlimab has shown promising signs of clinical activity in advanced and metastatic penile squamous cell carcinoma with no new safety signals. Objective response rate was 16.7% and three patients had a partial response. Median progression-free survival was 2.0 months and median overall survival was 7.2 months. One patient experienced a grade 3 treatment-related adverse event. The results of this phase II ORPHEUS study provide rationale for further investigation of retifanlimab for penile cancer.

中文翻译：

---

阴茎癌的免疫治疗

单药瑞替凡利单抗在晚期和转移性阴茎鳞状细胞癌中显示出有希望的临床活性迹象，但没有新的安全信号。客观缓解率为 16.7%，其中 3 名患者出现部分缓解。中位无进展生存期为 2.0 个月，中位总生存期为 7.2 个月。一名患者经历了 3 级治疗相关不良事件。这项 II 期 ORPHEUS 研究的结果为进一步研究瑞替凡利单抗治疗阴茎癌提供了理论基础。